tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Natera Targets Endometrial Cancer With New Signatera Trial, Expanding Its MRD Opportunity
PremiumCompany AnnouncementsNatera Targets Endometrial Cancer With New Signatera Trial, Expanding Its MRD Opportunity
1M ago
Natera’s SCORE Study Builds Real-World Evidence for Cancer MRD Testing
Premium
Company Announcements
Natera’s SCORE Study Builds Real-World Evidence for Cancer MRD Testing
1M ago
Natera: Accelerating MRD Momentum, Revenue Outperformance, and Improving Cash Profile Support Buy Rating
Premium
Ratings
Natera: Accelerating MRD Momentum, Revenue Outperformance, and Improving Cash Profile Support Buy Rating
1M ago
Natera price target raised to $280 from $240 at TD Cowen
PremiumThe FlyNatera price target raised to $280 from $240 at TD Cowen
1M ago
Exelixis, Natera announce collaboration on STELLAR-316 trial
Premium
The Fly
Exelixis, Natera announce collaboration on STELLAR-316 trial
1M ago
Natera initiated with a Buy at Citi
Premium
The Fly
Natera initiated with a Buy at Citi
1M ago
Natera price target raised to $285 from $260 at Canaccord
PremiumThe FlyNatera price target raised to $285 from $260 at Canaccord
2M ago
Natera publishes findings from CALGB/SWOG 80702 study in JAMA Oncology
Premium
The Fly
Natera publishes findings from CALGB/SWOG 80702 study in JAMA Oncology
2M ago
NeoGenomics announce Natera withdrawal of appeal in patent litigation
Premium
The Fly
NeoGenomics announce Natera withdrawal of appeal in patent litigation
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100